Skip to main content
SpringerLink
Log in

A role for oncostatin M in inflammatory bowel disease

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A new study identifies oncostatin M (OSM) as a potential biomarker and therapeutic target for anti-tumor necrosis factor (TNF)-refractory inflammatory bowel disease (IBD), and pinpoints mucosal stromal cells as key players in OSM-mediated inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: OSM and OSMR are upregulated in severe anti-TNF-therapy-refractive IBD.

Kim Caesar/Springer Nature

References

  1. Molodecky, N.A. et al. Gastroenterology 142, 46–54 (2012).

    Article  Google Scholar 

  2. Guerra, I. & Bermejo, F. Clin. Exp. Gastroenterol. 7, 359–367 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Feagan, B.G. et al. N. Engl. J. Med. 369, 699–710 (2013).

    Article  CAS  Google Scholar 

  4. Feagan, B.G. et al. N. Engl. J. Med. 375, 1946–1960 (2016).

    Article  CAS  Google Scholar 

  5. Sands, B.E. et al. Inflamm. Bowel Dis. 23, 97–106 (2017).

    Article  Google Scholar 

  6. West, N.R. et al. Nat. Med. 23, 579–589 (2017).

    Article  CAS  Google Scholar 

  7. Hermanns, H. Cytokine Growth Factor Rev. 26, 545–558 (2015).

    Article  CAS  Google Scholar 

  8. Sanchez, A. et al. J. Interferon Cytokine Res. 23, 193–201 (2003).

    Article  CAS  Google Scholar 

  9. Beigel, F. et al. PLoS One 9, e93498 (2014).

    Article  Google Scholar 

  10. Sandborn, W.J. et al. Gastroenterology 146, 85–95 (2014).

    Article  CAS  Google Scholar 

  11. Kullberg, M.C. et al. J. Exp. Med. 203, 2485–2494 (2006).

    Article  CAS  Google Scholar 

  12. Kullberg, M.C. et al. Infect. Immun. 69, 4232–4241 (2001).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 DK044319, R01 DK051362, R01 DK053056 and R01 DK088199 to R.S.B.; and T32 DK007533 to W.M.K.).

Author information

Authors and Affiliations

  1. Walter M. Kim and Richard S. Blumberg are in the Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.,

    Walter M Kim & Richard S Blumberg

  2. Arthur Kaser is in the Division of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Cambridge, UK.,

    Arthur Kaser

Authors
  1. Walter M Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arthur Kaser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard S Blumberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard S Blumberg.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, W., Kaser, A. & Blumberg, R. A role for oncostatin M in inflammatory bowel disease. Nat Med 23, 535–536 (2017). https://doi.org/10.1038/nm.4338

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.4338

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation